Immunotherapeutic Agents in Breast Cancer

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

This video reviews the latest trials and research on immunotherapeutic agents being tested in breast cancer.

In this video, Leisha A. Emens, MD, PhD, of the Sidney Kimmel Cancer Center, reviews some of the challenges to treating breast cancer patients with an immunotherapeutic approach and highlights the latest trials and research on different immunotherapies being tested in this setting, including PD-1 and PD-L1 blockade in patients with triple-negative breast cancer as well as other subtypes.

Emens gave a presentation on this topic at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Related Content
Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

Russ Conroy
February 25th 2025
Article

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate Higher Risk of ICANS in Patients With NHL

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate Higher Risk of ICANS in Patients With NHL

Tim Cortese
February 18th 2025
Article

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

Ariana Pelosci
February 18th 2025
Article

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Ide-Cel Yields High Response Rates in Post-Transplant Myeloma Patients

Ide-Cel Yields High Response Rates in Post-Transplant Myeloma Patients

Kristi Rosa
February 17th 2025
Article

Idecabtagene vicleucel led to high rates of MRD negativity in multiple myeloma who responded did not have complete responses to first-line therapy.